From: Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study
Cancer type | Polymorphism | Risk allele % Cases/controls | Genotype | Cases | Controls | OR | 95% CI |
---|---|---|---|---|---|---|---|
AML/MDS | TOP3A rs1563634 b | 75/66 | AA | 11 | 14 | 1.0c, d | - |
AG | 54 | 52 | 1.3 | 0.53–3.1 | |||
GG | 84 | 52 | 2.0 | 0.82–4.7 | |||
Malignant melanoma | 75/66 | AA | 12 | 14 | 1.0 | - | |
AG | 60 | 52 | 1.4 | 0.58–3.2 | |||
GG | 96 | 52 | 2.2 | 0.93–5.1 | |||
Bladder | 68/67 | AA | 3 | 19 | 1.0 | - | |
cancer | AG | 32 | 54 | 3.9 | 1.1–14 | ||
GG | 25 | 66 | 2.5 | 0.67–9.1 | |||
Breast cancer | 68/68 | AA | 19 | 16 | 1.0 | - | |
AG | 88 | 48 | 1.5 | 0.72–3.2 | |||
GG | 92 | 66 | 1.2 | 0.57–2.5 | |||
AML/MDS | TOP3A rs12945597 | 37/25 | GG | 61 | 64 | 1.0 | - |
GA | 63 | 49 | 1.3 | 0.76–2.2 | |||
AA | 22 | 5 | 4.9 | 1.7–14 | |||
Malignant melanoma | 32/25 | GG | 78 | 64 | 1.0 | - | |
GA | 72 | 49 | 1.2 | 0.74–2.0 | |||
AA | 18 | 5 | 3.0 | 1.0–8.4 | |||
Bladder | 36/30 | GG | 26 | 73 | 1.0 | - | |
cancer | GA | 25 | 49 | 1.4 | 0.75–2.8 | ||
AA | 9 | 17 | 1.5 | 0.58–3.7 | |||
Breast cancer | 31/26 | GG | 96 | 76 | 1.0 | - | |
GA | 84 | 40 | 1.7 | 1.0–2.7 | |||
AA | 20 | 15 | 1.1 | 0.52–2.3 | |||
AML/MDS | BLM rs401549 | 31/30 | AA | 65 | 57 | 1.0 | - |
AG | 75 | 51 | 1.3 | 0.77–2.1 | |||
GG | 9 | 10 | 0.77 | 0.29–2.0 | |||
Malignant melanoma | 36/30 | AA | 62 | 57 | 1.0 | - | |
AG | 90 | 51 | 1.6 | 0.98–2.7 | |||
GG | 16 | 10 | 1.5 | 0.61–3.5 | |||
Bladder | 37/30 | AA | 26 | 64 | 1.0 | - | |
cancer | AG | 24 | 67 | 0.90 | 0.47–1.7 | ||
GG | 10 | 8 | 3.1 | 1.1–8.7 | |||
Breast cancer | 34/33 | AA | 87 | 58 | 1.0 | - | |
AG | 94 | 61 | 1.0 | 0.65–1.6 | |||
GG | 19 | 12 | 1.1 | 0.48–2.4 | |||
AML/MDS | BLM rs2532105 | 16/12 | CC | 103 | 90 | 1.0 | - |
CT+TTe | 46 | 27 | 1.4 | 0.83–2.5 | |||
Malignant melanoma | 18/12 | CC | 109 | 90 | 1.0 | - | |
CT+TT | 59 | 27 | 1.8 | 1.1–3.2 | |||
Bladder cancer | 20/10 | CC | 40 | 111 | 1.0 | - | |
CT+TT | 20 | 28 | 2.1 | 1.0–4.2 | |||
Breast cancer | 17/13 | CC | 133 | 104 | 1.0 | - | |
CT+TT | 67 | 27 | 2.0 | 1.2–3.3 |